Macro Dragon: Is this Monday open different, or do we rally regardless? Macro Dragon: Is this Monday open different, or do we rally regardless? Macro Dragon: Is this Monday open different, or do we rally regardless?

Macro Dragon: Is this Monday open different, or do we rally regardless?

Macro 3 minutes to read
Kay Van-Petersen

Global Macro Strategist

Summary:  Macro Dragon highlights the wk ahead, checks in on the Coronavirus as well as shares views strategically & tactically.


(These are solely the views & opinions of KVP, & do not constitute any trade or investment recommendations. By the time you synthesize this, things may have changed.)

2020-Feb-10

 

Macro Dragon:Is this Monday open different?

 

The Week Ahead…

  • Central bank wise, we have decision out of New Zealand (rates expected to be held at 1.00%) & Mexico (Rates expected to be cut to 7.00% from 7.25%). There is quite a bit of Fed speak, with Powell set to testify before the Senate banking Panel. Also on same theme Lagarde will be speaking before the EC. We’ll also be hearing from RBA’s Lowe & Norges Bank’s Olsen.
  • Econ wise, CPI & PPI out of China, alongside loan data are likely to be ignored given the focus on the virus. We do also have CPI & retail sales out of the US, that is likely to be very much not ignored. Lastly IP & Flash GDP data out of Europe will be key.
  • Lastly for WK 7, it will be interesting to see if the New Hampshire primaries (Tue Feb 11 US time) will be just a touch better than the slow-motion-train-crash that was the Iowa Caucuses – which likely resulted in Trump being the real winner & Peter-B getting some wind knocked out of his sail. Other candidates really starting to take aim at Peter-B.
  • The Macro Dragon Slam-dunk-presidential trade is for Sanders, Warren or Bloomberg to take Peter-B as VP, then its game over. At 38, he’d get max 4yrs as VP (if they win), then potentially 8yrs as President after.
  • Its also going to be a long US wkd towards end of this wk, as they got Trump day on Feb 17th (Presidents Day, can see all the liberals heading to work anyway – not! That would be pretty funny though).
  • Markets will continue to focus on the Virus… as ideally we should start to see numbers drop off in China… i.e. +2wks period incubation period is over given the excellent decision to extend the lunar new year holiday that technically started on Jan 24th. Its worth noting that as China gets back into business slowly this wk, a lot of companies are urging remote working initiatives for that can do so

 

2019-nCoV Update Mon Asia Mrn 10 Feb & Thoughts…

  • We’ve expanded our thoughts this wk with a combination of updates, potential scenarios around opportunities & risk surrounding the Novel Coronavirus (a.k.a. 2019-nCoV / Wuhan Coronavirus) on “Speechless…” Thu 6 Feb, on Wed 5 Feb, on Tue 4 Feb, start of WK 6 Mon 3 Feb, here on Fri 31 Jan, here on Thu 30 Jan, here on Wed 29 Jan & here on Tue 28 Jan.
  • Also on Fri 7th Macro Dragon also included the context piece & thoughts of how the virus eventually plays out – combination of burning itself out as summer kicks into the Northern Hemisphere (granted break-outs in Southern Hemisphere possible) and/or the more likely case that it just become another seasonal flu bug that has to be contended with – similar to the US swine flu virus that broke out in 2009 & ended with over 60m Americans infected, over 270m globally & likely a conservative c. +300,000 deaths. Two key differences between that & now: 1. It was c. 10yrs ago when the social media volume was at 1x rather than today’s 11x and it was the US & not China – which lets be honest, western media & governments like to beat up relative to their own peers/neighbors.
  • Key risk to this view is that there is something a lot more dangerous about this virus than we know – which again given that we are seeing treatments & infections abroad, is likely a low probability. As to the risks of mutations, that a risk in all viruses & the truth is they are constantly mutating – it’s the extent of the mutation. For context according the the US Centers for Disease Control & Prevention, so far in this flu season in the US 19m have been infected, 180,000 had to end up in hospital & 10,000 have died.
  • Whilst the markets –  & China Equity Markets in particular – rallied tremendously last wk with new highs being seen in the S&P, the Macro Dragon remains skeptical at best on China/Asia Equity rally & would be bearish vs. having a long bias again the US. Again as the Macro Dragon has said from the first wk of covering the outbreak, we are back in a world of US outperformance vs. RoW, with a reflexivity twist. Strategically, one cannot own enough US duration – as all roads lead to a Fed that will need to cut. Tactically, it’s been a dice game to KVP, where if you are not staring at the screens all day, you can be in & out of profit on being either long or short. Its not to say the opportunities are not there – there always are opportunities (KVP totally missed the move by MAS & the weaker SGD), yet you need to be on point through all the regional trading sessions – and/or focus on an event that no one else is paying attention to.

Quick update & thoughts on the Virus since the Fri check in:

  • China slowly starts to come back to work this wk – albeit it could be weeks, potentially months in some cases before we are back to the production in the economy firing on all engines.
  • As of this Mon 10 morning, the China Figures we are getting are at c. 40,300 confirmed cases, +900 deaths & +3,000 recovered.  
  • Out of China the countries with confirmed cases over 10 are:
  • Japan 96,
  • Singapore 43
  • Hong Kong 36
  • Thailand 32,
  • South Korea 27
  • Taiwan 18
  • Malaysia 17
  • Australia 15
  • Germany 14
  • Vietnam 14
  • United States 12
  • France 11
  • Macau 10

 

Below bears a re-read or initial read if you missed previously…

This is a replay segment from Fri’s Macro Dragon – again due to its importance, key part to bear in mind here is what time-horizon are you playing & do your horizons/views match your exposure

Note these were prior to the huge melt-up that we had in wk #6 (Last wk). So question is, does it play out this into next wk… or does the bullish euphoria continue. Is there just too much liquidity in the system, for markets to care about the deflationary hit that China is going to take and/or are markets, just looking through all this as just a hiccup before we get China stimulus?

[From WK 5]

  • Here are a few other thoughts around the virus from the rest of the dream team at SaxoStrats – Key summary as captured by our CIO & Chief Strategist Steen Jakobsen, the near-term deflationary shock of the virus is not yet priced into markets, the economy, policy makers & companies – Jakobsen is envisaging a potential scenario where the Fed cuts 3x this year! Currently for the Mar 18, Apr 29 & Jun 10 meetings the implied probability of a Fed Cut (it was hikes prior to the mtg earlier this wk) are 14%, 28% & 55%.

Have a fantastic, gratitude & abundant filled wkd ahead everyone, stay healthy as well as keep your mind open to profitable & abundant opportunities. Life happens for us, not to us.  



Namaste,

-KVP

-

Some Anchor Pieces from #SaxoStrats:

Disclaimer

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.